GlassScriptPhysician profile
Katie J Holnbeck
NPI 1982992533
$7,702.02
in general payments reported to CMS, 2019-2025
29 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,851 · 2020: $430 · 2021: $728 · 2022: $1,257 · 2023: $812 · 2024: $1,310 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.17 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $902.91 | 2019-2025 | Cequa |
| Allergan, INC. | $898.22 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $509.51 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $502.07 | 2019-2021 | |
| Shire North American Group INC | $489.17 | 2019 | |
| Abbvie INC. | $388.04 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $381.73 | 2020-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $350.38 | 2019-2022 | |
| Alcon Vision LLC | $347.74 | 2022-2025 | Simbrinza, Tryptyr, Eysuvis |
| Novartis Pharmaceuticals Corporation | $322.84 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $299.88 | 2021-2022 | |
| Harrow Eye, LLC | $295.78 | 2024-2025 | Vevye, Iheezo |
| Rxsight INC | $279.85 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $278.19 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $234.26 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $217.76 | 2024-2025 | Tepezza |
| Dompe US, INC. | $203.05 | 2022-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $166.03 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Spheric |
| Tarsus Pharmaceuticals, INC. | $157.35 | 2024-2025 | Xdemvy |
| Halozyme INC | $91.47 | 2022-2025 | Hylenex Recombinant |
| Sight Sciences, INC. | $74.45 | 2020-2022 | |
| Alimera Sciences, INC. | $61.21 | 2022-2024 | Yutiq, Iluvien |
| Biotissue Holdings INC. | $47.37 | 2020-2022 | |
| Thea Pharma INC. | $46.05 | 2024-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $44.46 | 2020-2023 | Tecnis Simplicity |
| Astellas Pharma US INC | $33.66 | 2024 | Izervay |
| Glaukos Corporation | $27.34 | 2019 | |
| Apellis Pharmaceuticals, INC. | $27.33 | 2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $23.92 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Holnbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.